



(11) **EP 0 784 979 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
23.07.1997 Bulletin 1997/30

(51) Int Cl. 5: **A61K 38/17**  
 // (A61K38/17, 47:10),  
 (A61K38/17, 47:14)

(21) Application number: **97300299.1**

(22) Date of filing: **17.01.1997**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL**  
**PT SE**  
 Designated Extension States:  
**AL LT LV RO SI**

- Dodd, Steven Witt  
 Indianapolis, Indiana 46254 (US)
- Pekar, Allen Howard  
 Indianapolis, Indiana 46220 (US)

(30) Priority: **07.02.1996 GB 9602408**  
**19.01.1996 US 10229**

(74) Representative: Hudson, Christopher Mark et al  
 Lilly Industries Limited  
 European Patent Operations  
 Eri Wood Manor  
 Windlesham Surrey GU20 6PH (GB)

(71) Applicant: **ELI LILLY AND COMPANY**  
 Indianapolis, Indiana 46285 (US)

(72) Inventors:  
 • Beals, John Michael  
 Indianapolis, Indiana 46278-1853 (US)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Obesity protein formulations**

(57) The present invention discloses a soluble parenteral formulation, comprising obesity protein and

a preservative selected from the group consisting of alkylparaben, chlorobutanol, or a mixture thereof.

**BEST AVAILABLE COPY**

**EP 0 784 979 A2**